

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10144	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT03375307
10146	Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer	ETCTN-wide	No	Breast	https://clinicaltrials.gov/ct2/show/NCT03606967
10186	A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma	ETCTN-wide	Yes	Brain	https://clinicaltrials.gov/ct2/show/NCT03604978
10204	Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03816345
10214	Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT03816332
10273	A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT03983824

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10276	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies	ETCTN-wide (in PII)	Yes	Gastrointestinal, Solid tumors (dose escalation)	https://clinicaltrials.gov/ct2/show/NCT04068194
10285	Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285
10292	DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03907475
10299	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients	ETCTN-wide	No	Lymphoma, Solid tumors (no specified mutations)	https://clinicaltrials.gov/study/NCT06223542
10301	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	ETCTN-wide	Yes	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04071236
10335	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	ETCTN-wide	No	Leukemia, Lymphoma	https://clinicaltrials.gov/ct2/show/NCT04301076

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10355	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies	ETCTN-wide	No	Solid tumors (mutations), solid tumor (dose escalation), gynecologic	https://clinicaltrials.gov/ct2/show/NCT04585958
10358	Phase 1/1B study of DS8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)	ETCTN-wide	No	Gastrointestinal, Solid tumors (dose escalation), Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04704661
10366	A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT04172532
10371	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response	ETCTN-wide	No	Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04550494
10401	A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma	ETCTN-wide	No	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04494113
10422	Abemaciclib and Olaparib for Recurrent Ovarian Cancer	ETCTN-wide	No	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10433	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors	ETCTN-wide	No	Solid tumors (no specified mutations), Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04840589
10440	A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis	ETCTN-wide	No	Myeloma	https://clinicaltrials.gov/ct2/show/NCT04847453
10466	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04981509
10483	Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04963153
10499	Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas	ETCTN-wide	No	Lymphoma, Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05053971
10507	A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05019716

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10490	Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05142241
10492	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer	ETCTN-wide	Yes	Head and neck	https://clinicaltrials.gov/ct2/show/NCT05172245
10496	A Phase II Trial of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	ETCTN-wide	No	Head and neck	https://clinicaltrials.gov/ct2/show/NCT05172258
10486	Phase 2 Trial of the Combination of the BET Inhibitor, ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05327010
10495	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations	ETCTN-wide	No	Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05372614
10504	A Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05333458

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10508	A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL)	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05272384
10449	A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer	Limited (for dose escalation)	No	Breast	https://clinicaltrials.gov/ct2/show/NCT05111561
10509	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors	ETCTN-wide	No	ST escalation, Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05372640
10512	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	ETCTN-wide	Yes	Lung	https://clinicaltrials.gov/ct2/show/NCT05198830
10237	A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents	Limited	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT03816319
10464	A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05411094

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10525	A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer	ETCTN-wide	No	Breast	https://clinicaltrials.gov/ct2/show/NCT05422794
10487	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation	ETCTN-wide	No	Genitourinary, Endocrine	https://clinicaltrials.gov/ct2/show/NCT05691465
10500	Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05627245
10528	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors	ETCTN-wide	No	ST Mutations	https://clinicaltrials.gov/ct2/show/NCT05687110
10479	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors	ETCTN-wide	No	Endocrine, Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05687123
10505	A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma	ETCTN-wide	No	Brain	https://clinicaltrials.gov/ct2/show/NCT05432804
10527	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Pepsertib (M3814) in Combination with the ATR Inhibitor M1774	ETCTN-wide	No	ST Mutations	https://clinicaltrials.gov/ct2/show/NCT05687136

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10522	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05685602
10538	Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT05600894
10546	Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer	ETCTN-wide	No	Breast	https://clinicaltrials.gov/ct2/show/NCT05673200
10553	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients	ETCTN-wide	No	Head and Neck	https://clinicaltrials.gov/ct2/show/NCT05669664
10558	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetium 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors	ETCTN-wide	No	Endocrine	https://clinicaltrials.gov/ct2/show/NCT05724108
10561	Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab	Limited	No	Solid Tumors, NOS	https://clinicaltrials.gov/ct2/show/NCT05715281

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10563	A phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (Doxil®) in patients with metastatic leiomyosarcoma and other soft tissue sarcomas	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05711615
10556	Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma	ETCTN-wide	No	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05836571
10597	A Phase 1 trial of APG-1252 (pelcitoclast) and cobimetinib in recurrent ovarian and endometrial cancers	ETCTN-wide	No	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT05691504
10577	Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors	Limited	No	Solid tumor (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05691517
10572	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774	Limited	No	ST Mutations	https://clinicaltrials.gov/ct2/show/NCT05691491
10590	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05886036
10596	A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/ct2/show/NCT05886049

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10579	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors	Limited	No	Solid tumors (dose escalation), GI	https://clinicaltrials.gov/ct2/show/NCT05803382
10601	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	ETCTN-wide	No	Lymphoma	https://clinicaltrials.gov/study/NCT06015880
10559	A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with FGFR-TACC Gene Fusion	ETCTN-wide	No	Brain	https://clinicaltrials.gov/ct2/show/NCT05859334
10603	Phase II Study of M1774 in Refractory SPOP-Mutant Prostate Cancer	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT05828082
10592	A Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/study/NCT05947500
10614	A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers	ETCTN-wide	No	Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT05896839
10605	Phase I Trial of ZEN-3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06102902

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10608	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06050252
10612	A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma	ETCTN-wide	No	Myeloma	https://clinicaltrials.gov/study/NCT06169215
10629	A Phase I Dose Finding and Phase II Randomized Trial of ladademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer	ETCTN-wide	No	Lung	https://clinicaltrials.gov/study/NCT06287775
10647	Phase I/Ib Study of Eribulin in Combination with ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)	ETCTN-wide	No	Breast	https://clinicaltrials.gov/study/NCT06590558
10653	A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06802523
10637	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia	Limited	No	Leukemia	https://clinicaltrials.gov/study/NCT06311227

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10554	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression	Limited for escalation ; wide for expansion	No	Gastrointestinal; Solid tumors (dose escalation)	https://clinicaltrials.gov/study/NCT06364410
10667	Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors	Limited	No	Solid Tumors, NOS	https://clinicaltrials.gov/study/NCT06606990
10630	Phase 1 Trial of ladademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06514261
10636	Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer	ETCTN-wide	No	Genitourinary	https://clinicaltrials.gov/study/NCT06439836
10657	Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients with Retinoblastoma (Rb)+ Sarcomas	Limited	No	Sarcoma	https://clinicaltrials.gov/study/NCT06498648
10674	A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)	Limited	No	Leukemia	https://clinicaltrials.gov/study/NCT06484062

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10620	A Phase 1b Trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma	ETCTN-wide	No	Myeloma	https://clinicaltrials.gov/study/NCT06465316
10655	Phase I Clinical Trial of CA-4948 in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06696768
10675	A Randomized Phase II Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)	ETCTN-wide	No	Leukemia	https://clinicaltrials.gov/study/NCT06661915
10664	Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia	ETCTN-wide	No	Leukemia, Lymphoma	Not available currently.
10670	Phase 1 study of 5-fluorouracil in combination with abemaciclib in metastatic, refractory CRC	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06654037

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10660	Histologically or cytologically documented locally advanced or metastatic KRASG12C-mutant non-small cell lung cancer (NSCLC) that has previously been treated with a KRASG12C inhibitor AND an immune checkpoint inhibitor (ICI) and/or chemotherapy, either given concurrently or sequentially.	ETCTN-wide	No	Lung	Not available currently.
10699	A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma	ETCTN-wide	No	Brain	https://clinicaltrials.gov/study/NCT06860594
10666	A Dose-Finding Phase I Study of Bone-targeted Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors with Skeletal Metastases	ETCTN-wide	No	Solid Tumors, NOS	Not available currently.
10703	A Phase I/II Trial of Sapanisertib in Combination with Cabozantinib in β -Catenin-Mutated Hepatocellular Carcinoma	Limited for escalation ; wide for Phase II	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06811116
10707	Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	https://clinicaltrials.gov/study/NCT06730100
10695	Lintuzumab-Ac225 monotherapy for patients with hypomethylating agent-refractory myelodysplastic syndrome	ETCTN-wide	No	Leukemia	Not available currently.
10702	A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy	ETCTN-wide	No	Lymphoma	Not available currently.

All ETCTN Trials: Updated March 10, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10706	A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery	ETCTN-wide	No	Head and Neck	Not available currently.
10708	A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia	ETCTN-wide	No	Leukemia	Not available currently.
10713	A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma	Limited	No	Brain	Not available currently.
10717	Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma	ETCTN-wide	No	Lymphoma	Not available currently. NEW!
10727	Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma	ETCTN-wide	No	Lymphoma	Not available currently. NEW!